Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Oncology|June 23, 2011
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myelomaWeijun Fu, Kay Delasalle, Jialei Wang, et al.
Cancer|March 29, 2002
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of boneRichard B Wilder, Chul S Ha, James D Cox, et al.
Cancer|June 16, 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myelomaAthanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, et al.
Cancer|December 6, 2011
Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based studyHaijun Wang, Yiming Chen, Fanglin Li, et al.
Leukemia & Lymphoma|May 27, 2004
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myelomaMichele L Donato, Ana Aleman, Richard E Champlin, et al.
Blood|April 9, 2004
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisAlok C Bharti, Shishir Shishodia, James M Reuben, et al.
Leukemia & Lymphoma|September 17, 2004
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progressionMeletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, et al.
Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Blood|May 6, 2003
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trialsSergio Giralt, William Bensinger, Mark Goodman, et al.
Cancer|February 4, 2005
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal functionSundar Jagannath, Bart Barlogie, James R Berenson, et al.
Pageof 3